70 related articles for article (PubMed ID: 1563535)
1. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.
Scelles V; Raccah D; Alessi MC; Vialle JM; Juhan-Vague I; Vague P
Diabete Metab; 1992; 18(1):38-42. PubMed ID: 1563535
[TBL] [Abstract][Full Text] [Related]
2. Hypofibrinolysis and insulin-resistance.
Juhan-Vague I; Vague P
Diabete Metab; 1991 May; 17(1 Pt 2):96-100. PubMed ID: 1936490
[TBL] [Abstract][Full Text] [Related]
3. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels.
Juhan-Vague I; Alessi MC; Raccah D; Aillaud MF; Billerey M; Ansaldi J; Philip-Joet C; Vague P
Thromb Haemost; 1992 Jan; 67(1):76-82. PubMed ID: 1615488
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
5. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
6. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man.
Vuorinen-Markkola H; Puhakainen I; Yki-Järvinen H
Thromb Haemost; 1992 Jan; 67(1):117-20. PubMed ID: 1615465
[TBL] [Abstract][Full Text] [Related]
7. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
9. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
Herlihy OM; Barrow BA; Grant PJ; Levy JC
Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
[TBL] [Abstract][Full Text] [Related]
10. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
[TBL] [Abstract][Full Text] [Related]
11. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects.
Pannacciulli N; De Mitrio V; Marino R; Giorgino R; De Pergola G
Obes Res; 2002 Aug; 10(8):717-25. PubMed ID: 12181379
[TBL] [Abstract][Full Text] [Related]
12. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.
Vague P; Juhan-Vague I; Alessi MC; Badier C; Valadier J
Thromb Haemost; 1987 Jun; 57(3):326-8. PubMed ID: 3310318
[TBL] [Abstract][Full Text] [Related]
13. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
Mertens I; Ballaux D; Funahashi T; Matsuzawa Y; Van der Planken M; Verrijken A; Ruige JB; Van Gaal LF
Thromb Haemost; 2005 Dec; 94(6):1190-5. PubMed ID: 16411393
[TBL] [Abstract][Full Text] [Related]
14. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
Kinik ST; Ozbek N; Yuce M; Yazici AC; Verdi H; Ataç FB
Thromb Haemost; 2008 Feb; 99(2):352-6. PubMed ID: 18278185
[TBL] [Abstract][Full Text] [Related]
15. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor (PAI) in obese men and obese women.
Cucuianu M; Lanczek M; Roman S
Rom J Intern Med; 1993; 31(3):183-92. PubMed ID: 8130756
[TBL] [Abstract][Full Text] [Related]
17. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
[TBL] [Abstract][Full Text] [Related]
18. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors.
De Pergola G; Pannacciulli N; Coviello M; Scarangella A; Di Roma P; Caringella M; Venneri MT; Quaranta M; Giorgino R
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):227-32. PubMed ID: 17400434
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
van Tits LJ; Arioglu-Oral E; Sweep CG; Smits P; Stalenhoef AF; Tack CJ
Neth J Med; 2005; 63(7):250-5. PubMed ID: 16093575
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
